Rosiglitazone r2408
Rosiglitazone (R2408) is a pharmaceutical compound developed by Merck Group. It is a synthetic thiazolidinedione derivative. The core function of Rosiglitazone is to act as a peroxisome proliferator-activated receptor gamma (PPAR-gamma) agonist.
Lab products found in correlation
6 protocols using rosiglitazone r2408
Triglyceride Monostearate and Rosiglitazone-Mediated Anti-Inflammatory Effects
Adipocyte Differentiation Assay
Cell Viability Assay with Rosiglitazone and GW9662
Osteoblast Differentiation Antibodies
Thiazolidinedione Compounds Acquisition
Rosiglitazone: PPAR-gamma agonist effects
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!